China Antibody Drug Conjugates Contract Manufacturing Market Forecast 2024-2032

The China antibody drug conjugates contract manufacturing market is expected to progress at a CAGR of 12.34% during the forecast period 2024-2032. Diverse enablers foster market growth, the rising demand for targeted therapies, the growing inclination towards contract manufacturing companies as an economical choice, the surging global cancer incidence, and advancements in drug conjugation technologies.

MARKET INSIGHTS

The China antibody drug conjugates contract manufacturing market is a vital segment of the country's pharmaceutical industry. With the rising incidence of cancer globally, there is an increasing demand for effective treatment options such as antibody drug conjugates. This demand has fueled the growth of contract manufacturing organizations (CMOs) specializing in ADC production, catering to both domestic and international pharmaceutical companies.

One of the key factors driving this market is the advancements in drug conjugation technologies. These technologies have enabled the development of more targeted and efficient ADCs, improving their efficacy and safety profiles. As a result, pharmaceutical companies are increasingly outsourcing ADC manufacturing to specialized CMOs in China, leveraging their expertise in this niche field.

Furthermore, collaborations between key players in the China ADC contract manufacturing market and global pharmaceutical firms have become more prevalent. These collaborations harness scientific knowledge, manufacturing capabilities, and regulatory expertise. They facilitate seamless production and delivery of high-quality ADCs, meeting the increasing demand for innovative cancer therapies in China and globally.

COMPETITIVE INSIGHTS

Some of the major companies in the China antibody drug conjugates contract manufacturing market include AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Lonza Group, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
The competitive landscape is the theoretical explanation of the key companies based on factors such as market share.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 85908

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.6. MAJOR MARKET FINDINGS
- 2.6.1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)
- 2.6.2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. RISING DEMAND FOR TARGETED THERAPIES
- 3.1.2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE
- 3.1.3. SURGING GLOBAL CANCER INCIDENCE
- 3.1.4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING
- 3.2.2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS
- 3.2.3. STRINGENT REGULATORY REQUIREMENTS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. RISING DEMAND FOR ADCS
- 4.1.2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE
4.2. PESTLE ANALYSIS
- 4.2.1. POLITICAL
- 4.2.2. ECONOMICAL
- 4.2.3. SOCIAL
- 4.2.4. TECHNOLOGICAL
- 4.2.5. LEGAL
- 4.2.6. ENVIRONMENTAL
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
- 4.4.1. GROWTH PROSPECT MAPPING FOR CHINA
4.5. MARKET CONCENTRATION ANALYSIS
4.6. KEY BUYING CRITERIA
- 4.6.1. EXPERTISE AND EXPERIENCE
- 4.6.2. MANUFACTURING CAPACITY
- 4.6.3. REGULATORY COMPLIANCE
- 4.6.4. QUALITY CONTROL
- 4.6.5. COST
4.7. REGULATORY FRAMEWORK

5. MARKET BY PHASE

5.1. CLINICAL PHASE
- 5.1.1. MARKET FORECAST FIGURE
- 5.1.2. SEGMENT ANALYSIS
5.2. COMMERCIAL PHASE
- 5.2.1. MARKET FORECAST FIGURE
- 5.2.2. SEGMENT ANALYSIS

6. MARKET BY LINKER

6.1. CLEAVABLE LINKERS
- 6.1.1. MARKET FORECAST FIGURE
- 6.1.2. SEGMENT ANALYSIS
6.2. NON-CLEAVABLE LINKERS
- 6.2.1. MARKET FORECAST FIGURE
- 6.2.2. SEGMENT ANALYSIS

7. MARKET BY CONDITION

7.1. MYELOMA
- 7.1.1. MARKET FORECAST FIGURE
- 7.1.2. SEGMENT ANALYSIS
7.2. LYMPHOMA
- 7.2.1. MARKET FORECAST FIGURE
- 7.2.2. SEGMENT ANALYSIS
7.3. BREAST CANCER
- 7.3.1. MARKET FORECAST FIGURE
- 7.3.2. SEGMENT ANALYSIS
7.4. OTHER CONDITIONS
- 7.4.1. MARKET FORECAST FIGURE
- 7.4.2. SEGMENT ANALYSIS

8. COMPETITIVE LANDSCAPE

8.1. KEY STRATEGIC DEVELOPMENTS
- 8.1.1. MERGERS & ACQUISITIONS
- 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 8.1.3. PARTNERSHIPS & AGREEMENTS
8.2. COMPANY PROFILES
- 8.2.1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)
  - 8.2.1.1. COMPANY OVERVIEW
  - 8.2.1.2. SERVICES LIST
  - 8.2.1.3. STRENGTHS & CHALLENGES
- 8.2.2. LONZA GROUP
  - 8.2.2.1. COMPANY OVERVIEW
  - 8.2.2.2. SERVICES LIST
  - 8.2.2.3. STRENGTHS & CHALLENGES
- 8.2.3. MERCK KGAA
  - 8.2.3.1. COMPANY OVERVIEW
  - 8.2.3.2. SERVICES LIST
  - 8.2.3.3. STRENGTHS & CHALLENGES
- 8.2.4. SAMSUNG BIOLOGICS
  - 8.2.4.1. COMPANY OVERVIEW
  - 8.2.4.2. SERVICES LIST
  - 8.2.4.3. STRENGTHS & CHALLENGES
- 8.2.5. WUXI BIOLOGICS
  - 8.2.5.1. COMPANY OVERVIEW
  - 8.2.5.2. SERVICES LIST
  - 8.2.5.3. STRENGTHS & CHALLENGES

Product Code: 85908

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 9: LIST OF MERGERS & ACQUISITIONS
TABLE 10: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 11: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR CHINA
FIGURE 4: MARKET CONCENTRATION ANALYSIS
FIGURE 5: KEY BUYING CRITERIA
FIGURE 6: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY PHASE, IN 2023
FIGURE 7: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLINICAL PHASE, 2024-2032 (IN $ MILLION)
FIGURE 8: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COMMERCIAL PHASE, 2024-2032 (IN $ MILLION)
FIGURE 9: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY LINKER, IN 2023
FIGURE 10: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)
FIGURE 11: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY NON-CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)
FIGURE 12: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY CONDITION, IN 2023
FIGURE 13: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY MYELOMA, 2024-2032 (IN $ MILLION)
FIGURE 14: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LYMPHOMA, 2024-2032 (IN $ MILLION)
FIGURE 15: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)
FIGURE 16: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY OTHER CONDITIONS, 2024-2032 (IN $ MILLION)